Ernexa Therapeutics (ERNAW) Net Income towards Common Stockholders (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$5.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 32.87% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.4 million (up 75.27% YoY) and the FY2025 annual result came in at -$14.1 million, up 68.35% from the prior year.
• Net Income towards Common Stockholders fell to -$5.5 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.2 million in Q3 2025 to a low of -$26.6 million in Q3 2024.
• A 5-year average of -$6.5 million and a median of -$5.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders plunged 375.84% — and 2025, when it soared 95.34%.
• Tracing ERNAW's Net Income towards Common Stockholders over 5 years: stood at -$4.5 million in 2022, then tumbled by 37.0% to -$6.2 million in 2023, then advanced by 6.4% to -$5.8 million in 2024, then jumped by 73.82% to -$1.5 million in 2025, then slumped by 264.64% to -$5.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$5.5 million (Q1 2026), -$1.5 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.